The AACR Project GENIE Data Model, recently released by the AACR GENIE consortium, is an open-access tool designed to...
Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard...
One of the world’s largest cancer research conferences, the AACR Annual Meeting 2019, came to an end with a...
Over the course of AACR Annual Meeting 2019, there were 213 presentations on incredibly exciting clinical trials. This is...
In the past couple of decades, progress against cancer has created a new generation of survivors. Today, more than...
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
The AACR-Bayer Innovation and Discovery Grants program supports researchers who are seeking to develop new treatment options for cancers...
Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or...
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology...
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including...
Persistent infections from pathogens are a major cause of cancer incidence worldwide. An analysis from 2012 indicates that more...